ALKemist Bio is a startup based in Italy. Its most recent tracked round is Seed. Brouky records 2 investors associated with the company.
ALKemist Bio develops cellular immunotherapies targeting ALK-positive cancers by engineering T cells with high-affinity T cell receptors (TCRs) and chimeric antigen receptors (CARs) to recognize and eliminate tumor cells expressing the ALK oncogene.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.